Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.
DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Visit For Sample Pages:
https://www.delveinsight.com/sample-request/hemophilia-a2030-market
Hemophilia A Market Analysis
-
Total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.
-
According to DelveInsight’s analysis, the highest prevalent population of Hemophilia A is in the United States with 14,200 cases in 2017.
-
In the 7MM, approximately 30% of severe hemophilia A cases, i.e., 6,305 patients affected by inhibitors. In addition to this, 70% of the Hemophilia A cases were observed without inhibitors in 2017.
-
Among the 7MM, the US accounts for 51% USD of the overall market size of hemophilia A in 2017.
-
Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy.
Hemophilia A Market
The Hemophilia A market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hemophilia A market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
Hemophilia A Epidemiology
Hemophilia A is a general term for a group of rare bleeding disorders caused by a congenital deficiency of certain clotting factors. The main form of hemophilia is hemophilia A; it is different from Hemophilia B. The main difference between them is that Hemophilia B is associated with deficiency in factor IX (9) while Hemophilia A is associated with deficiency of factor VIII. More than 80% of people with hemophilia have hemophilia A.
The Hemophilia A epidemiology section covers insights about historical and current Hemophilia A patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
Hemophilia A Drugs Uptake and Key Market Players
The Hemophilia A Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia A market or expected to get launched in the market during the study period. The analysis covers Hemophilia A market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The Key players in Hemophilia A market include such as
-
Biomarin Pharmaceutical
-
Novo Nordisk
-
Sanofi
-
Pfizer
-
Catalyst Biosciences
-
OPKO Biologics
-
Spark Therapeutics
-
Sangamo therapeutics
and others.
For more details visit:
https://www.delveinsight.com/report-store/hemophilia-a2030-market